Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New program aims to stop dangerous low blood sugar in diabetes patients

NCT ID NCT06353217

Knowledge-focused Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested a new program to help prevent low blood sugar (hypoglycemia) in people with diabetes who take medications that can cause it. The program included a patient survey and a toolkit for doctors. The study involved 35 patients and their primary care providers at one clinic. The main goal was to see if the program was acceptable and practical for use in a busy primary care setting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hypoglycemia Prevention Program (patient survey and provider toolkit)
What this could lead to
If this program works well, it could lead to a larger study and eventually a simple way for doctors to help patients avoid dangerous low blood sugar episodes.
What could go wrong
This is a very small pilot study with only 35 people, so results may not apply to everyone. It focuses on whether the program is acceptable, not yet on whether it actually prevents low blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

35 people

The number who actually took part.

Started

May 2024

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria for patients: * Age 18 years or older * Diabetes mellitus by electronic health record review * Treatment with any of the following medication classes: insulin, sulfonylureas, meglitinides * Community dwelling (not residing in long-term care or a skilled nursing facility) * Receiving primary care from a participating primary care provider at Johns Hopkins Internal Medicine at Green Spring Station * The patient's primary care provider approves their participation Exclusion criteria for patients: * Significant cognitive impairment or dementia * Receiving hospice or end of life care * Any other serious illness or condition not compatible with participation as determined by the investigators * Planning to leave area prior to end of study * Investigator discretion Exclusion Criteria for continuous glucose monitoring (not required for study participation): * History of allergic skin reaction to adhesive * Implantable pacemaker Inclusion criteria for primary care providers: * Practicing at Johns Hopkins Internal Medicine Green Spring Station Exclusion criteria for primary care providers: * Planning to leave their position prior to end of study * Not serving as primary care provider for any included patient Inclusion criteria for clinic staff: * Participating in check-in at Johns Hopkins Internal Medicine Green Spring Station Exclusion criteria for clinic staff * Planning to leave their position prior to end of study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus hypoglycemia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus Hypoglycemia

Contacts and locations

Locations

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.